�
Exclusive breastfeeding can increment a child's risk of developing rachitis because breast milk alone does not provide decent levels of vitamin D, a critical ingredient that helps to absorb calcium and build strong finger cymbals, the New York Times reports. Rickets develops when a child's vitamin D levels ar too low-toned and is characterized by the curved of a child's legs and the softening of other castanets. Some children are symptomless.
Darker-skinned children have a greater risk of vitamin D inadequacy than other children because they do not take in vitamin D as easily through the skin. Sunlight enables the skin to synthesize vitamin D.
Cases of nutritional rickets among infants and loretta Young children in the U.S. have been "accumulating over the concluding decade or so," and children with the term are more likely to be black or swarthy and have been breastfed exclusively for an extended period of time without vitamin supplementation, according to the Times. Some experts say that an increase in infants being solely breastfed, more children drink soda or juice and less milk, and children spending less time in the sunshine could contribute to rachitis re-emerging as a public health problem, the Times reports.
According to the Times, while physicians have known for days that undivided breastfeeding is associated with vitamin D deficiency in infants and rickets, many are "loath to tell anything that might deter breastfeeding." The American Academy of Pediatrics in 2003 recommended that infants world Health Organization are only breastfed receive vitamin D drops day-after-day.
According to one study on rickets and vitamin D that included mostly black and Hispanic infants and toddlers, 40% of the participants had abject levels of vitamin D, 12% were vitamin D deficient, 13 children showed evidence of bone loss and trey children had signs of rickets. The study, published in the June number Archives of Pediatrics & Adolescent Medicine, also establish that breastfeeding without vitamin supplementation was a significant risk factor for rickets.
Study generator Catherine Gordon, director of Children's Hospital Boston's bone health plan, said, "I completely support breastfeeding, and I think breast milk is the perfect nutrient, and the healthiest way to nourish an infant. However, we're finding so many mothers are vitamin D deficient themselves that the milk is thence deficient, so many babies can't sustain their levels up." She added, "They may lead off their lives vitamin D deficient, and then all they're acquiring is vitamin D deficient breast milk" (Rabin, New York Times, 8/26).
Reprinted with kind permission from http://www.kaisernetwork.org. You canful view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for e-mail delivery at http://www.kaisernetwork.
Monday 1 September 2008
Friday 22 August 2008
Multaq(R) (dronedarone) Granted FDA Priority Review For Patients With Atrial Fibrillation
�Sanofi-aventis
(EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug
Administration (FDA) has assigned priority limited review status for its New Drug
Application (NDA) for Multaq(R) (dronedarone). The priority review time period
begins on July 31, 2008.
The priority review is given to applications in which a new
indication or new drug product, if approved, has the voltage to deliver a
safe and effective therapy where no satisfactory alternative exists
compared to currently useable therapies or marketed products.
A registration dossier is also under regulatory limited review by the European
Medicines Agency (EMEA) for a Marketing Authorization Application.
"We are pleased that the FDA has designated Multaq(R) for precedency
review," said Marc Cluzel, sanofi-aventis Senior Vice President, R&D for
sanofi-aventis. "This follows the exciting results of the landmark ATHENA
study that showed Multaq(R) significantly decreased the risk of
cardiovascular hospitalizations or death from any causal agent in patients with
Atrial Fibrillation."
Atrial fibrillation is a major cause of hospitalization and mortality
and affects about 2.5 million people in the United States, as well as 4.5
million people in the European Union and is rising as a growing public
health concern due to an ripening population. Patients suffering from atrial
fibrillation have double the risk of death, an increased risk of stroke and
cardiovascular complications, including congestive heart failure.
Furthermore atrial fibrillation considerably impairs patients' lives,
mainly because of their inability to execute normal daily activities due to
complaints of palpitations, chest botheration, dyspnoea, fatigue or
light-headedness.
About Multaq(R) (dronedarone)
Dronedarone (brand bring up Multaq(R)) is an investigational new discussion
for patients with atrial fibrillation, which has been discovered and
developed by sanofi-aventis for the bar and discourse of patients
with atrial fibrillation or atrial flutter. Dronedarone is a multi-channel
blocker that affects calcium, potassium and sodium channels and has
anti-adrenergic properties. Dronedarone does not hold the i radical
and did not show any evidence of thyroid or pulmonary toxicity in clinical
trials.
About Sanofi Aventis
Sanofi-aventis, a ahead global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as outlined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include intersection development, product potential projections
and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the
words "expects," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes that
the expectations reflected in such forward-looking statements are
sane, investors ar cautioned that forward-looking information and
statements are issue to various risks and uncertainties, many of which
are hard to call and loosely beyond the control of
sanofi-aventis, that could causal agency actual results and developments to take issue
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among former things, the uncertainties underlying in research and
development, future clinical data and analysis, including post selling,
decisions by regulatory government, such as the FDA or the EMEA, regarding
whether and when to approve whatsoever drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial potential of such products candidates, the absence of guarantee
that the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutical alternatives as
well as those discussed or identified in the public filings with the SEC
and the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' yearly report on Form 20-F for the year over December 31,
2007. Other than as required by applicable law of nature, sanofi-aventis does not
undertake any obligation to update or revise any advanced
information or statements.
Sanofi Aventis
http://www.sanofi-aventis.com
More info
(EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug
Administration (FDA) has assigned priority limited review status for its New Drug
Application (NDA) for Multaq(R) (dronedarone). The priority review time period
begins on July 31, 2008.
The priority review is given to applications in which a new
indication or new drug product, if approved, has the voltage to deliver a
safe and effective therapy where no satisfactory alternative exists
compared to currently useable therapies or marketed products.
A registration dossier is also under regulatory limited review by the European
Medicines Agency (EMEA) for a Marketing Authorization Application.
"We are pleased that the FDA has designated Multaq(R) for precedency
review," said Marc Cluzel, sanofi-aventis Senior Vice President, R&D for
sanofi-aventis. "This follows the exciting results of the landmark ATHENA
study that showed Multaq(R) significantly decreased the risk of
cardiovascular hospitalizations or death from any causal agent in patients with
Atrial Fibrillation."
Atrial fibrillation is a major cause of hospitalization and mortality
and affects about 2.5 million people in the United States, as well as 4.5
million people in the European Union and is rising as a growing public
health concern due to an ripening population. Patients suffering from atrial
fibrillation have double the risk of death, an increased risk of stroke and
cardiovascular complications, including congestive heart failure.
Furthermore atrial fibrillation considerably impairs patients' lives,
mainly because of their inability to execute normal daily activities due to
complaints of palpitations, chest botheration, dyspnoea, fatigue or
light-headedness.
About Multaq(R) (dronedarone)
Dronedarone (brand bring up Multaq(R)) is an investigational new discussion
for patients with atrial fibrillation, which has been discovered and
developed by sanofi-aventis for the bar and discourse of patients
with atrial fibrillation or atrial flutter. Dronedarone is a multi-channel
blocker that affects calcium, potassium and sodium channels and has
anti-adrenergic properties. Dronedarone does not hold the i radical
and did not show any evidence of thyroid or pulmonary toxicity in clinical
trials.
About Sanofi Aventis
Sanofi-aventis, a ahead global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as outlined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include intersection development, product potential projections
and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the
words "expects," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes that
the expectations reflected in such forward-looking statements are
sane, investors ar cautioned that forward-looking information and
statements are issue to various risks and uncertainties, many of which
are hard to call and loosely beyond the control of
sanofi-aventis, that could causal agency actual results and developments to take issue
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among former things, the uncertainties underlying in research and
development, future clinical data and analysis, including post selling,
decisions by regulatory government, such as the FDA or the EMEA, regarding
whether and when to approve whatsoever drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial potential of such products candidates, the absence of guarantee
that the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutical alternatives as
well as those discussed or identified in the public filings with the SEC
and the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' yearly report on Form 20-F for the year over December 31,
2007. Other than as required by applicable law of nature, sanofi-aventis does not
undertake any obligation to update or revise any advanced
information or statements.
Sanofi Aventis
http://www.sanofi-aventis.com
More info
Tuesday 12 August 2008
New Research Questions Use Of Common Fertility Treatments
�
A raw study promulgated on bmj.com
has found that fertility is not improved in sterile couples wHO have
been treated with long-established medical interventions. The team of
researchers lED by the University of Aberdeen has called for UK and
national guidelines to be reviewed with this new evidence that
challenges current practices.
In the UK, one in seven couples experience infertility. Of these, about
25% of the infertility is unexplained, and the criterion treatment
includes a body of common interventions that have been used for years
and have been issued by the National Institute for Health and Clinical
Excellence (NICE).
The research squad set out to compare two specific interventions with
expectant management (i.e., no intervention). From quatern teaching hospitals
and a district general hospital in Scotland, they recruited a sample of
580 women who own had unexplained infertility for over deuce years. The
women were arbitrarily assigned such that one group had no medical
intervention and tried naturally to become pregnant, a second radical
took oral clomifene citrate (CC) to correct subtle ovulatory
disfunction, and a third group received unstimulated intra-uterine
insemination (IUI) of sperm.
During the course of the study, 101 women became pregnant and had a
alive birth. The birth pace for women with no intervention was 17%, and
the rates for the oral CC group and the IUI group were 14% and 23%,
respectively. According to the researchers, the 6% difference between
the IUI and the non-intervention group is no large enough for the
results to suggest a meaningful and significant advance in the live
parentage rate.
Many women suffered from side effects that included: pain, bloating,
hot flushes, nausea and headaches. These affected approximately 10 to 20% of
women, most of whom were taking oral CC. Also, it is worth noting that
satisfaction was higher in the groups of women being actively treated -
as they were reassured by the treatment process - compared to women who
received no intervention.
"These interventions, which have been in use for many years, ar
unlikely to be more effective than no treatment. These results
challenge stream practice, as endorsed by a national guideline in the
UK," conclude the authors.
Tarek El-Toukhy and Yacoub Khalaf (Assisted Conception Unit at Guy's
and St Thomas' NHS Foundation Trust) write in an incidental editorial
that: "As a direct resolution of the lack of evidence, many couples with
unexplained infertility endure (and even request) expensive,
potentially hazardous, and often unnecessary treatments." There is a
need for high quality clinical trials as well as better information for
patients to determine the best treatments in light of strength and
adverse effects. El-Toukhy and Khalaf also call for the current NICE
guidelines to be reviewed with this inquiry in mind.
Clomifene citrate or unstimulated intrauterine insemination
compared with anticipative management for unexplained sterility:
pragmatic randomized controlled trial
S Bhattacharya, K Harrild, J Mollison, S Wordsworth, C Tay, A Harrold,
D McQueen, H Lyall, L Johnston, J Burrage, S
Grossett, H Walton, J Lynch, A
Johnstone, S Kini, A Raja, A Templeton
BMJ (2008). 337: a716.
doi:10.1136/bmj.a716
Click
Here to View Journal Web Site
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
A raw study promulgated on bmj.com
has found that fertility is not improved in sterile couples wHO have
been treated with long-established medical interventions. The team of
researchers lED by the University of Aberdeen has called for UK and
national guidelines to be reviewed with this new evidence that
challenges current practices.
In the UK, one in seven couples experience infertility. Of these, about
25% of the infertility is unexplained, and the criterion treatment
includes a body of common interventions that have been used for years
and have been issued by the National Institute for Health and Clinical
Excellence (NICE).
The research squad set out to compare two specific interventions with
expectant management (i.e., no intervention). From quatern teaching hospitals
and a district general hospital in Scotland, they recruited a sample of
580 women who own had unexplained infertility for over deuce years. The
women were arbitrarily assigned such that one group had no medical
intervention and tried naturally to become pregnant, a second radical
took oral clomifene citrate (CC) to correct subtle ovulatory
disfunction, and a third group received unstimulated intra-uterine
insemination (IUI) of sperm.
During the course of the study, 101 women became pregnant and had a
alive birth. The birth pace for women with no intervention was 17%, and
the rates for the oral CC group and the IUI group were 14% and 23%,
respectively. According to the researchers, the 6% difference between
the IUI and the non-intervention group is no large enough for the
results to suggest a meaningful and significant advance in the live
parentage rate.
Many women suffered from side effects that included: pain, bloating,
hot flushes, nausea and headaches. These affected approximately 10 to 20% of
women, most of whom were taking oral CC. Also, it is worth noting that
satisfaction was higher in the groups of women being actively treated -
as they were reassured by the treatment process - compared to women who
received no intervention.
"These interventions, which have been in use for many years, ar
unlikely to be more effective than no treatment. These results
challenge stream practice, as endorsed by a national guideline in the
UK," conclude the authors.
Tarek El-Toukhy and Yacoub Khalaf (Assisted Conception Unit at Guy's
and St Thomas' NHS Foundation Trust) write in an incidental editorial
that: "As a direct resolution of the lack of evidence, many couples with
unexplained infertility endure (and even request) expensive,
potentially hazardous, and often unnecessary treatments." There is a
need for high quality clinical trials as well as better information for
patients to determine the best treatments in light of strength and
adverse effects. El-Toukhy and Khalaf also call for the current NICE
guidelines to be reviewed with this inquiry in mind.
Clomifene citrate or unstimulated intrauterine insemination
compared with anticipative management for unexplained sterility:
pragmatic randomized controlled trial
S Bhattacharya, K Harrild, J Mollison, S Wordsworth, C Tay, A Harrold,
D McQueen, H Lyall, L Johnston, J Burrage, S
Grossett, H Walton, J Lynch, A
Johnstone, S Kini, A Raja, A Templeton
BMJ (2008). 337: a716.
doi:10.1136/bmj.a716
Click
Here to View Journal Web Site
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
Wednesday 6 August 2008
'Mummy' dearest at international boxoffice
Sequel takes in $61.2 mile from 27 countries
With 1 month to go before the trek back to school begins, the blockbuster action adventures keep gushing out in assembly-line mode, with the past weekend's new
With 1 month to go before the trek back to school begins, the blockbuster action adventures keep gushing out in assembly-line mode, with the past weekend's new
Dani Ro
Artist: Dani Ro
Genre(s):
R&B: Soul
Electronic
Discography:
Enplastico 2003
Year: 2007
Tracks: 11
El Repartidor De Hi
Year:
Tracks: 15
Thergothon
Artist: Thergothon
Genre(s):
Metal
Discography:
Fhtagn-Nagh Yog-Sothoth
Year: 2005
Tracks: 4
Stream From The Heavens
Year: 1994
Tracks: 6
Fhtagn-Nag Yog-Sothoth
Year: 1991
Tracks: 4
Wednesday 2 July 2008
Cover Story: Jen's Baby Plan
In September 2005, just months after her split from then-husband Brad Pitt, Jennifer Aniston confessed to Vanity Fair her desire to have a child.
"There's an amazing man who's wandering the streets right now, who's the father of my children," she said. "In five years, I would hope to be married and have a kid...Maybe it's a fairytale, but I believe in happily ever after."
Three years since making that statement, Jen seems to have finally found her prince charming in a tall, dark and handsome younger man, nine years her junior to be exact, John Mayer.
"I've never seen Jen this happy � or this in love," a pal of the actress tells OK!. "Not since Brad."
Just three months into their relationship, the couple has jet-setted across the world, shacked up for cozy evenings together in her Beverly Hills home and even met each other's inner circles (John has gotten the thumbs up from Jen's BFF Courteney Cox and her husband David Arquette).
And, as of last week, the actress flew to Europe to accompany John, 30, on his European tour, where on June 28 witnesses spotted the two getting hot and heavy at La Famiglia restaurant in London. That same day, Jen was the proud girlfriend, taking photos of her man from the side of the stage while he performed in concert at the Hard Rock Calling Festival.
It's no wonder Jen wants to move fast. While she has a body and energy level most girls in their 20's would die for, not even she can fight time. Jen, who turns 40 on her next birthday, knows that now is her chance to have that long-wished for baby, and she wants to have it with John!
"It wouldn't be much of a surprise at all if they moved in together by the year's end," a friend of Jen's tells OK!. "And if they do, you can bet that there will be serious discussions about having children."
For the entire story on Jen's pregnancy plan, pick up the new OK! � on sale everywhere Wednesday!
See Also
Keira Knightley - Knightley Miller Bond Over Babies
KEIRA KNIGHTLEY and SIENNA MILLER bonded on the set of new movie THE EDGE OF LOVE - because they share a passion for children.
The stars' roles in the picture required them to carry around young children and it made them considered having kids of their own.
Miller says, "As a woman you have instincts and you do get a bit broody, definitely. It didn't last, though."
Knightley adds, "The babies were amazing, absolutely gorgeous."
See Also
Arctics: 'Winehouse should take a break'
Arctic Monkeys guitarist Jamie Cook has said that Amy Winehouse should "take a break" from music.
Cook's band avoided watching Winehouse's performance at Glastonbury on Saturday, choosing to drink beers backstage instead, according to The Mirror.
Commenting on the singer's current health, Cook said: "Amy is a fantastic talent but she shouldn't be on stage when she's in such a state.
"Only a week ago she was seriously ill and now she's performing at gigs. She needs to take a break from performing and sort herself out."
Winehouse apparently checked back into hospital following her performance at the festival.
See Also
Cook's band avoided watching Winehouse's performance at Glastonbury on Saturday, choosing to drink beers backstage instead, according to The Mirror.
Commenting on the singer's current health, Cook said: "Amy is a fantastic talent but she shouldn't be on stage when she's in such a state.
"Only a week ago she was seriously ill and now she's performing at gigs. She needs to take a break from performing and sort herself out."
Winehouse apparently checked back into hospital following her performance at the festival.
See Also
Andre Gagnon
Artist: Andre Gagnon
Genre(s):
New Age
Jazz
Pop
Discography:
The Most Beloved Andre Gagnon Cd2
Year: 2003
Tracks: 12
The Most Beloved Andre Gagnon Cd1
Year: 2003
Tracks: 13
Escape
Year: 2002
Tracks: 17
Saisons
Year: 2001
Tracks: 15
L'histoire D'amour Et Adieu
Year: 2001
Tracks: 17
Histoires Revees
Year: 2001
Tracks: 10
Solitude
Year: 2000
Tracks: 14
Resonance
Year: 2000
Tracks: 11
Presque Bleu
Year: 2000
Tracks: 10
Noel
Year: 2000
Tracks: 12
Les Jours Tranquilles
Year: 2000
Tracks: 10
Eden
Year: 2000
Tracks: 12
Reves D'automne
Year: 1999
Tracks: 16
La Musique D'andre Gagnon Automne
Year: 1999
Tracks: 12
Wondering Married Life
Year: 1998
Tracks: 12
Le Pianiste
Year: 1998
Tracks: 16
Impressions Romantique
Year: 1994
Tracks: 10
L'eternel Retour
Year: 1989
Tracks: 10
Comme Dans Un Film
Year: 1986
Tracks: 8
Impressions Vol.2
Year: 1983
Tracks: 10
Impressions Vol.1
Year: 1983
Tracks: 9
Neiges
Year: 1975
Tracks: 9
La Musique D'andre Gagnon Hiver
Year:
Tracks: 12
Image
Year:
Tracks: 9
Andre Gagnon Au Centre Molson
Year:
Tracks: 22
Age,35
Year:
Tracks: 10
Classical musician and composer Andre Gagnon began playing the forte-piano in front he regular began school. Born in 1942 in Quebec, he went to Paris at the historic period of 19 to written report on a subsidization from the Canadian government. After returning to Canada, he worked with Claude Leveillee for heptad years. He then turned solo and went to London to record with the London Baroque Orchestra and subsequently, the Hamburg Philharmonic Orchestra. Of his more than 20 albums from 1964 to 1993, Neiges (1976) was the most popular; it was a bestseller and won a Canadian Juno Award. Gagnon has besides recorded in the discotheque and pop w. C. Fields.
The Honey Drippers
Prosecutors again play sex tape at R. Kelly's child porn trial in Chicago
CHICAGO - Prosecutors at R. Kelly's child pornography trial Thursday replayed for jurors the graphic sex tape at the centre of the case, working to lay to rest any doubts in jurors' minds that the R&B singer and an underage female are on the video.
But defence lawyers said again in closing arguments that neither Kelly nor the alleged victim are the people on the tape.
As the video played, assistant state's attorney Shauna Boliker told jurors the man on the tape is Kelly - who denies accusations he videotaped himself having sex with a female as young as 13 - and that he controlled the encounter.
"We're going to see his direction," Boliker said. He is "directing her to dance, where to stand, when to stop urinating," she said.
At one point in the video, entered into evidence as "People's Exhibit No. 1," the female dances and urinates on the floor - the man out of view. Back in view, he has sex with her. In one scene near the end of the video, alluded to in one count of the indictment, the man urinates on the female.
The month-long trial has centred on whether the R&B superstar is the man who appears on the 27-minute videotape, and whether a female who also appears on it is underage.
Kelly, 41, has pleaded not guilty to 14 counts of child pornography. Both he and the alleged victim, now 23, deny being on the tape and neither testified at trial.
Defence lawyer Sam Adam Jr. told jurors that charges against Kelly came about because people were trying to extort money from the Grammy winner because the man on the tape "may favour him."
"That's what this is about money, money, money," Adam said.
He also suggested that prosecutors pressured people into testifying against Kelly.
Over seven days presenting their case, prosecutors called 22 witnesses, including several childhood friends of the alleged victim and four of her relatives who identified her as the female on the video. Some said she had referred to Kelly as her "godfather."
In just two days, Kelly's lawyers called 12 witnesses. They included three relatives of the alleged victim who testified they did not recognize her as the female on the tape.
Adam said that the alleged victim's relatives know it's not her on the video because "any solid man in that family, any solid woman in that family would have gone over there and broken his legs, would have gone over there and beat the crap out of him."
The family also would have gotten an order of protection against Kelly, but none of that happened, Adam said.
-Don Babwin contributed to this report.
See Also
Stevie Wonder - Wonder Dedicates Tour To Late Mother
Soul legend STEVIE WONDER has dedicated his forthcoming European tour to his late mother - insisting he will keep her memory alive by performing.
The star was devastated when Lula Mae Hardaway passed away in 2006 and took an extended hiatus from the music business.
But it was only recently that Wonder realised his mother wouldn't have wanted him to give up his career - and he has now vowed to get back on stage and dedicate his live shows to spreading her message of goodwill.
He says, "After I lost my mother in May of 2006, I had said that I wasn't going to perform for a while.
"But I got the message (from my mother) to go and spread the message, celebrating some of the feats that we have, such as coming together and fighting against apartheid. ...We cannot forever think that we will have the blessings that we have without staying on point."
Wonder played his first U.S. tour in over a decade last year (07) and his upcoming European trek will begin in Birmingham, England on 8 September (08). It will conclude on 28 September in Paris, France.
See Also
Hrsta
Artist: Hrsta
Genre(s):
Indie
Rock
Discography:
Ghosts Will Come And Kiss Your Eyes
Year: 2007
Tracks: 9
Le Divan Orange, Montreal
Year: 2006
Tracks: 9
Stem Stem in Electro
Year: 2005
Tracks: 8
Billy Talent
Artist: Billy Talent
Genre(s):
Other
ROck: Alternative
Alternative
Rock: Hard-Rock
Indie
Discography:
666 (Live)
Year: 2007
Tracks: 17
Billy Talent II
Year: 2006
Tracks: 13
The Ex
Year: 2004
Tracks: 2
River Below
Year: 2004
Tracks: 2
Try Honesty
Year: 2003
Tracks: 11
Billy Talent
Year: 2003
Tracks: 12
Punk gospeller foursome Billy Talent used to be known as Pezz back in their Streetsville, Ontario, senior high days. But by 1999, the quadruple -- vocalizer Ben Kowalewicz, guitar player Ian D'Sa, bassist Jon Gallant, and drummer Aaron Solowoniuk -- had adoptive a new soubriquet and were making their way in Toronto with the self-released Watoosh! LP under their swath. The Try Honesty EP followed in 2001; it lED to strong local buzz, pic encouraging larger touring acts of the Apostles, and an eventual demo deal with EMI. The band entered the studio in former 2003 with producer Gavin Brown and emerged with its eponymic debut in July, which was slated for a September spill on Atlantic. Billy Talent got the son out during that summer with a one-armed bandit on Lollapalooza and a series of dates with the Buzzcocks. Before they knew it, the band had not only garnered an impressive following, merely as well a veer of Juno (Best New Group, Group of the Year and Album of the Year) and MuchMusic (Best Video, Best Rock Video) Awards to their constitute. Billy Talent strike the studio in February 2005 to start work on their sophomore offering. Submitting to fan requests, the radical re-released Pezz's Watoosh! that September earlier the highly anticipated and volatile II appeared in June 2006. A handful of festivals and U.K. dates were played prior to disbursal the rest of the summer on the Warped Tour.
Subscribe to:
Posts (Atom)